Despite the shaky start to 2009, the biotech sector regained its financial footing. Biotech indices were up, as were offerings and partnership monies. Excluding collaborations, the sector raised a total of $24.3 billion. Although initial public offerings showed signs of resuscitation (at least 13 more companies are now in the queue), follow-on financings came in above $6 billion—the second-best year over the past decade.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yang, W. 2009: Turning the corner. Nat Biotechnol 28, 116 (2010). https://doi.org/10.1038/nbt0210-116
Issue Date:
DOI: https://doi.org/10.1038/nbt0210-116
This article is cited by
-
Is silence still golden? Mapping the RNAi patent landscape
Nature Biotechnology (2011)
